How close are we to a cAMP- and cGMP-theory-based pharmacological therapy for fragile X syndrome?
Recent advances in targeting cAMP and cGMP pathways offer hope for treating fragile X syndrome, a leading cause of inherited intellectual disability. PDE4 and PDE2 inhibitors have shown promise in animal models, improving memory, social behavior, and cognitive function. Clinical trials are underway, raising optimism for future therapies.
Authors
- Barbara Bardoni (ORCID: https://orcid.org/0000-0001-6411-1517)
- Thomas Maurin
- Carole Gwizdek
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Syneos Health (United States) (US)
- Institut de Pharmacologie Moléculaire et Cellulaire (FR)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.xcrm.2025.101972
- Citations
- 2
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.63